Athersys (ATHX) Reports Q3 Loss of $0.07/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
November 15, 2021 4:05 PM ESTPositive topline data for ARDS study and completion of enrollment in Japan ischemic stroke study are important milestones for development and potential commercialization of MultiStem® cell therapy
Management to host conference call at 4:30 pm EST today
CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2021 and provided a corporate update.
The third quarter brought several important milestones in the development and potential commercialization of MultiStem® cell therapy, stated Mr. William (B.J.)... More
